Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

Researchers have conducted one of the largest eye studies in the world to reveal new insights into retinal thickness, highlighting its potential in the early detection of diseases like type 2 diabetes ...

AI-powered research on one of the largest eye studies to date has created the most detailed maps of the retina ever produced.

Researchers have conducted one of the largest eye studies in the world to reveal new insights into retinal thickness, highlighting its potential in the early detection of diseases like type 2 diabetes ...

Thyroid eye disease (TED) therapy Tepezza – the top asset in Amgen's $26 billion takeover of Horizon in 2023 – could be facing competition from an easier-to-dose alternative from Sling ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

This prospective case-control study included 85 patients with lung involvement related to the COVID-19 virus and a group of ...

and REGENXBIO Inc. The continued evolution of treatment protocols and imaging modalities for the management of retinal diseases offers the potential to further optimize visual and anatomical ...

Continuous Glucose Monitor Data Predicts Type 1 Diabetes Complications Jan. 15, 2025 — Data from continuous glucose monitors can predict nerve, eye and kidney damage caused by type 1 diabetes ...

Incomplete blinking is associated with meibomian gland dropout, meibum quality, and lipid layer thickness, and may predict DED.